Novavax Inc vs Wipro Limited — how do they compare? Novavax Inc trades at $7.92 (market cap $1.30B), while Wipro Limited trades at $1.98 (market cap $19.22B). The key difference: Wipro Limited is far larger — about 14.8× Novavax Inc's market cap, and Wipro Limited pays a 4.35% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | WIT | |
|---|---|---|
Market Cap | $1.30B | $19.22B |
Sector | Health | Technology |
52-Week High | $11.19 | $3.06 |
52-Week Low | $6.22 | $1.78 |
Enterprise Value | $879.40M | $17.30B |
Dividend Yield | — | 4.35% |
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $7.95, up 2.71% with a bullish technical signal despite negative profitability metrics. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 but negative net income margins. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook while cutting expenses. Analyst sentiment remains positive with 74% buy ratings.
Investment outlook balances strong partnerships and pipeline potential against persistent cash burn and negative equity. The Sanofi collaboration and Matrix-M adjuvant platform offer growth catalysts, but operational losses and high debt levels present significant risks. Stock appears undervalued on some metrics but requires careful monitoring of cash flow sustainability.
WIT trades at $2.02, up 1.51% today, with a neutral technical signal and bearish moving average trend. The company reported a net income margin of 13.92% and ROE of 16.09% for 2025, with revenue of $890.88 billion. Recent earnings have missed expectations, but partnerships with Databricks and ServiceNow aim to drive AI-led growth. Cash flow from operations remains strong at $169.43 billion, supporting a $0.02 dividend.
The outlook is mixed: valuation ratios like P/E of 15.25 and EV/EBITDA of 7.83 appear reasonable, but earnings misses and competitive pressures pose risks. Analyst sentiment is cautious with only 19% buy ratings. Key opportunities include AI expansion, while risks involve client spending cuts and margin pressure from wage increases.
Trailing returns across standard periods
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →